PubMed Health⌕ Search

PubMed · 10985724

Selective ring-opening reactions of

Abstract

The reactivity of strained [1]ferrocenophanes, [Fe(eta-C5H4)2ERx] (ERx = SiMe2, 1a: SiMePh, 1b; SnR2, 1c), towards boron halides has been investigated and has been shown to provide a facile pathway to ferrocene derivatives functionalized with Lewis acidic boron centers. The boron halides RBX2 (R = Cl, Ph, fc; X = Cl, Br) (fc = Fe(eta-C5H4)2) lead to selective cleavage of the Si-Cp bonds in 1a and 1b to give, depending on the reaction stoichiometry, functionalized mono- or diferrocenylboranes RnB [(eta-C5H4)Fe(eta-C5H4SiMe2Cl)](3-n) (2a: R = Cl, n = 2; 2b: R = Cl, n = 1; 2c: R = Ph, n = 1) and RnB[(eta-C5H4)Fe(eta-C5H4SiMePhCl)](3-n) (2d: R = Cl, n = 2) in high yields. Compounds 2a-d were characterized by multinuclear NMR spectroscopy, mass spectrometry, and by single-crystal X-ray diffraction (for 2b). Most likely due to steric constraints, a triferrocenylborane was not obtained even from the reaction of BCl3 with an excess of 1a, whereas facile formation of the diferrocenylphenylborane 2c from PhBCl2 and two equivalents of 1a was observed. Selective hydrolysis of the B-Cl bonds of chlorodiferrocenylborane 2b in the presence of trace amounts of water led to the silylated tetranuclear ferrocene complex [(ClMe2Sifc)2B-O-B(fcSiMe2Cl)2] (3) without cleavage of the Si-Cl bonds. The structure of 3 was confirmed by an X-ray diffraction study. Studies of the reactivity of the higher Group 14 homologue of 1a and 1b, the tin-bridged [1]ferrocenophane 1c, revealed that facile addition of B-Cl bonds occurs across the Sn-Cp bonds to yield the 1-stannyl-1'-borylferrocenes [(ClMes2Sn)fc(BClR)] (4a: R = Cl; 4b: R = Ph; Mes = 2,4,6-Me3C6H2). The new synthetic methodology can be extended to bifunctional Lewis acids such as the bis(boryl)ferrocene 1,1'-fc(BBr2)2, which affords the linear boron-bridged ferrocene trimer 1,1'-[fc[B(Br)fcSiMe2Br]2] 5 in 54% isolated yield. In order to incorporate the functionalized ferrocenylboranes into polymer structures, compound 2c was reduced with Li[BEt3H] to give the silicon-hydride functionalized species [PhB[(eta-C5H4)Fe(eta-C5H4SiMe2H)]2] (6), which was then used as a capping reagent in the transition metal catalyzed polymerization of 1a. This process leads to the incorporation of the ferrocenylborane unit into the main chain of a poly(ferrocenylsilane) to afford [PhB-[(fcSiMe2)(n-1)fcSiMe2H]2] (7).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Jakle, A Berenbaum, AJ Lough, I Manners. 2000-08-04. Selective ring-opening reactions of. https://doi.org/10.1002/1521-3765(20000804)6%3A15%3C2762%3A%3Aaid-chem2762%3E3.0.co%3B2-l

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗